早期发生的中性质和ADA2缺乏的混合表型:诊断和治疗的挑战
Sibel Kaplan Sarıkavak1, Özge Türkyılmaz Uçar2, Burcu Cil3
1Department of Pediatric Allergy and Clinical Immunology, University of Health Sciences, Istanbul Haseki Training and Research Hospital, Istanbul, Türkiye.
Frontiers in immunology
|October 20, 2025
概括
氨酸脱氨酶2缺乏症 (DADA-2) 通常呈现为中性质衰竭和混合免疫/炎症症状. 早期对ADA2基因的基因测试对于及时诊断和治疗这种罕见的自身炎症综合征至关重要.
科学领域:
- 免疫学 免疫学 免疫学
- 遗传学 是一个遗传学.
- 血液学 血液学 血液学
背景情况:
- 氨酸脱氨酶2缺乏症 (DADA-2) 是一种与ADA2基因突变相关的自身炎症综合征.
- ADA-2对于 purin代谢和免疫调节至关重要,DADA-2表现出各种症状,包括血管炎症,免疫调节失调以及纯红细胞失质和HLH等血液问题.
研究的目的:
- 详细介绍七名DADA-2患者的临床,人口和免疫学概况.
- 为了更好地了解DADA-2的血液学和免疫学方面.
- 为早期诊断和改善治疗策略提供见解.
主要方法:
- 从患者医疗记录中收集的数据.
- 进行了基因分析,淋巴细胞子集的流细胞计和ADA-2酶活性试验.
主要成果:
- 七名患者 (主要是男性) 呈现出血液问题,特别是中性质减退 (100%).
- 两名患者患有血细胞性淋巴细胞瘤 (HLH),导致42.8%的死亡率;HLH发生在没有确定的病毒触发因素的情况下.
- 骨髓分析显示低细胞性和T细胞透;基因型-表型相关性表明更严重的血液学参与与不可检测的ADA2活性或功能丧失突变. 三名患者在血造造细胞干细胞移植 (HSCT) 后实现了疾病逆转.
结论:
- DADA-2最初可以表现为孤立的中性衰竭,并且经常呈现混合的表型.
- HLH是DADA-2的严重并发症,可以独立于感染发生.
- 对ADA2突变的基因测试应该是先天性中性的标准,虽然基因型-表型相关性具有预后价值,但由于可变的残留酶活性,个性化管理至关重要.
相关概念视频
01:28Acute Pyelonephritis II: Diagnostic Studies and Management
308
Introduction:For diagnosing acute pyelonephritis, a comprehensive patient history is collected to identify symptoms such as dysuria, frequent or urgent urination, flank pain, or costovertebral angle (CVA) tenderness that may suggest a kidney infection.Physical ExaminationDuring the physical examination, CVA tenderness is assessed. This involves gentle percussion over the costovertebral angle, where tenderness often indicates a kidney infection.Diagnostic TestsUrinalysis: Used to identify white...
308
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
209
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
209